Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etripamil in Paroxysmal Supraventricular Tachycardia (NODE-302)
NCT03635996Phase 3Terminated
- Sponsor
- Milestone Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of etripamil in paroxysmal supraventricular tachycardia (PSVT), sponsored by Milestone Pharmaceuticals. Primary endpoint: Time to Conversion of an Episode of PSVT to Sinus Rhythm (SR) After Study Drug Administration at 18 months. Started Dec 2018; status: terminated.
02
Drugs
etripamil
03
Conditions
paroxysmal supraventricular tachycardia (PSVT)
Beyond the preview
Go deeper on NCT03635996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03635996.